Monday, January 17, 2022

Mexico grants emergency use approval for Merck’s COVID-19 pill

test

Mexico’s health regulator has granted authorization for emergency use of drugmaker Merck’s COVID-19 pill Molnupiravir, President Andres Manuel Lopez Obrador said on Friday.

The health regulator, COFEPRIS, was expected to soon also approve Pfizer’s Paxlovid pill to treat COVID-19, Lopez Obrador added at a regular news conference. Both medications were approved last month in the United States.

About Molnupiravir- the Merck COVID-19 pill

Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission. Additionally, pre-clinical and clinical data have shown molnupiravir to be active against the most common SARS-CoV-2 variants. Molnupiravir was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, and is being developed by Merck & Co., Inc. in collaboration with Ridgeback Biotherapeutics. Ridgeback received an upfront payment from Merck and also is eligible to receive contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. Any profits from the collaboration will be split between the partners equally. Since licensed by Ridgeback, all funds used for the development of molnupiravir have been provided by Merck and by Wayne and Wendy Holman of Ridgeback.

The drug was also evaluated for post-exposure prophylaxis in MOVe-AHEAD, a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study, which is evaluating the efficacy and safety of molnupiravir in preventing the spread of COVID-19 within households.

Comments

Latest Posts

LATEST NEWS

Comments